Scleroderma

Experts Provide a New Framework for Systemic Sclerosis Treatment

A multidisciplinary team of scleroderma specialists developed a framework for a comprehensive and sustainable approach to treating scleroderma.

Do Silver-Fiber Gloves Offer Additional Benefit for Patients With Raynaud Phenomenon?

Researchers investigated whether 8% silver-fiber gloves reduced the burden of Raynaud phenomenon in patients with scleroderma.

Efzofitimod Granted Orphan Drug Status for Systemic Sclerosis

In preclinical studies, efzofitimod was found to prevent inflammation and fibrosis in multiple animal models of systemic sclerosis and idiopathic pulmonary fibrosis.

MMP-7 May Serve as a Biomarker for Systemic Sclerosis-Associated Interstitial Lung Disease

Could matrix metalloproteinase-7 serve as a biomarker for predicting the course of systemic sclerosis-linked interstitial lung disease?

Reliability of Ultrasound and Elastography in the Assessment of Skin Involvement in SSc

Authors of a systematic review evaluated available literature assessing the role of ultrasound and elastography in skin involvement in systemic sclerosis.

Lung Function Decline Linked to Increased Risk for Hospitalization in Patients With SSc-ILD

Researchers evaluated the association between forced vital capacity decline and hospitalization events in patients with systemic sclerosis-associated interstitial lung disease.

The Scleroderma Foundation Evolves Into the National Scleroderma Foundation

The Scleroderma Foundation recently changed their name to the National Scleroderma Foundation to better inform the organization’s scope and work in the community.

Elicitation of Patient Preferences in Scleroderma May Inform Future RCT Design and Enrollment

Researchers explored the impact of elicitation of patient preferences in informing design, enrollment, and modifiable aspects of treatment in future randomized controlled trials.

Main Cause of Acute Hospitalization and Mortality Identified in Patients With Systemic Sclerosis

Researchers studied the causes and predictors of acute hospitalization and in-patient mortality in patients with systemic sclerosis (SSc).

Gastroprotective Agents Do Not Prevent ILD Risk in Patients With Systemic Sclerosis

Do gastroprotective and promotility agents prevent incident interstitial lung disease in patients with systemic sclerosis?